Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Inventory (2016 - 2025)

Historic Inventory for Myriad Genetics (MYGN) over the last 15 years, with Q3 2025 value amounting to $31.6 million.

  • Myriad Genetics' Inventory rose 2061.07% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.6 million, marking a year-over-year increase of 2061.07%. This contributed to the annual value of $27.5 million for FY2024, which is 2500.0% up from last year.
  • As of Q3 2025, Myriad Genetics' Inventory stood at $31.6 million, which was up 2061.07% from $28.7 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Inventory high stood at $31.6 million for Q3 2025, and its period low was $15.3 million during Q4 2021.
  • Moreover, its 5-year median value for Inventory was $22.5 million (2023), whereas its average is $22.7 million.
  • Its Inventory has fluctuated over the past 5 years, first plummeted by 4354.24% in 2021, then skyrocketed by 4610.39% in 2023.
  • Over the past 5 years, Myriad Genetics' Inventory (Quarter) stood at $15.3 million in 2021, then soared by 31.37% to $20.1 million in 2022, then increased by 9.45% to $22.0 million in 2023, then rose by 25.0% to $27.5 million in 2024, then increased by 14.91% to $31.6 million in 2025.
  • Its last three reported values are $31.6 million in Q3 2025, $28.7 million for Q2 2025, and $28.3 million during Q1 2025.